Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Penn Virginia Corporation (PVA): Soros Fund Management Increases Exposure To The Stock

Soros Fund Management has disclosed in a recent regulatory filing with the Security and Exchange Commission that it has decreased its stake in Penn Virginia Corporation (NYSE:PVA) to 8.40% from as much as 9.53%, or from 6.25 million shares to 6 million shares. The “economic exposure” to the stock, however, has decreased by less – in terms of percentage of Penn Virginia Corporation (NYSE:PVA) total outstanding shares – to 9.38%. Furthermore, in absolute terms, George Soros’ exposure to the oil and gas company increased to 6.7 million shares, with around 700,000 shares being in the form of cash-settled total return swap contracts. Because Penn Virginia Corporation (NYSE:PVA) has increased the number of total shares in circulation following a private placement, Soros’ stake has shrunk, in spite of stepping up its position.

hedge fund research

Additionally, Soros has reported that on July, 1 it sold call options on some 250,000 shares with an expiration date of July, 19 and a strike price of $17.

In a rare move that hardly describes Soros’ investing philosphy, the legendary investor engaged in activism with the company one month ago, sending a letter to the board of directors of Penn Virginia Corporation (NYSE:PVA) where it has raised concerns about the company’s recent missteps. Particularly, the investor has made reference to some underwhelming presentations at several conferences and issuance of preferred stock at a “significant discount”, following which the stock tumbled given the dilution. Indeed, in the last three months Penn Virginia Corporation (NYSE:PVA)’s stock fell close to 30%, erasing half of year-to-date gains.  Soros has reached its verdict, saying the company should be “promptly” sold, as there are “numerous” potential buyers ready to pay a handsome premium over the last trading price.

As the stock continues to head down and with Soros, which is the largest shareholder, pressing for a sale, Penn Virginia Corporation (NYSE:PVA) may become an attractive takeover target.

Disclosure: None

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!